// App-Quantinova.ai

: The Prognostic Value of TP53 Mutations Depends on Clinical Backgrounds in Pediatric Patients with Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Hiroo Ueno

Principal Investigators

  • Yusuke Shiozawa

  • Yasuhito Nannya

  • Yuka Iijima-Yamashita

  • Nobutaka Kiyokawa

  • Yuichi Shiraishi

  • Kenichi Chiba

  • Hiroko Tanaka

  • Tomoya Isobe

  • Masafumi Seki

  • Shunsuke Kimura

  • Hideki Makishima

  • Nobuyuki Kakiuchi

  • Keisuke Kataoka

  • Tetsuichi Yoshizato

  • Hiroyuki Tsukamoto

  • Dai Nishijima

  • Takao Deguchi

  • Kentaro Ohki

  • Atsushi Sato

  • Hiroyuki Takahashi

  • Yoshiko Hashii

  • Sadao Tokimasa

  • Junichi Hara

  • Yoshiyuki Kosaka

  • Koji Kato

  • Takeshi Inukai

  • Junko Takita

  • Toshihiko Imamura

  • Satoru Miyano

  • Atsushi Manabe

  • Keizo Horibe

  • Seishi Ogawa

  • Masashi Sanada

Medical Centers

  • Department of Surgery, Kyoto University, Kyoto, Japan

  • Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

  • Department of Biostatistics, The University of Tokyo, Tokyo, Japan

  • Clinical Rsch Cntr, National Hosp Organization, Nagoya Med Cntr, Nagoya, Japan

  • Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan

  • Laboratory of DNA information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

  • Group for Cancer Development and Progression, National Cancer Center Research Institute, Tokyo, Japan

  • Department of Pediatrics, Hiroshima University Graduate School of Bomedical Sciences, Hiroshima, Japan

  • Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan

  • Childrens Cancer Center, National Center of Child Health and Development, Tokyo, Japan

  • Miyagi Children's Hospital, Sendai, Japan

  • Toho University, Ota-Ku, JPN

  • Departmentof Pediatrics, Osaka University School of Medicine, Osaka, Japan

  • Osaka University Graduate School of Medicine, Suita, Japan

  • Department of Medical Oncology,Osaki Citizen Hospital, Osaki-Shi, Japan

  • Department of Hematology and Oncology, Shizuoka Childrens Hospital, Shizuoka, Japan

  • Department of Hematology and Oncology, Childrens Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya,

  • Department of Pediatrics, University of Yamanashi, Kofu, Japan

  • Department of Biostatistics, Kyoto Prefectural University of Medicine, Kyoto, Japan

  • Department of Pediatrics, St. Lukes International Hospital, Tokyo, Japan

  • Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Huddinge, Sweden

Locations

  • Japan

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Solid malignancies

Biomarkers

  • ETV6-RUNX1

  • Tumor protein p53

Drug/Treatment

  • TP53

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved